ESMO Media Releases

Immunotherapy, which works by enabling the body’s immune system to recognise and destroy cancer cells improves long-term overall survival in patients with advanced melanoma in results from large international studies reported at ESMO 2024

Studies reported at ESMO 2024 reveal new groups of women with early-stage endometrial and cervical cancers who gain clinically meaningful benefit from adding immunotherapy to current standard treatments, while a first-in-human study found ‘promising’ antitumour activity with a novel antibody drug conjugate (ADC) targeting the protein claudin 6 in heavily pretreated patients with ovarian and endometrial cancers

The ESMO Congress 2024 taking place 13-17 September in Barcelona, Spain, offers a comprehensive view of the current drug development landscape, with existing medicines demonstrating benefit in additional applications and new agents emerging in large numbers as the range of potential molecular targets for therapy continues to expand

The ESMO Congress 2024 will hold a press conference to introduce and discuss the “Eyes to the Future” Presidential Symposium 3, that will be presenting prominent approaches that have the potential to become increasingly effective and influential components of cancer treatment in the (near) future.

The European Society for Medical Oncology (ESMO) is calling on all actors of the oncology community to commit to improving the well-being of the cancer workforce and join in 11 actions outlined in a paper published today in ESMO Open

According to two international studies presented at the ESMO Congress 2024, women who breastfeed after receiving treatment for breast cancer, including those with a germline BRCA mutation (an inherited change in BRCA genes that significantly increases the risk of developing certain cancers, especially breast cancer), do not face an increased risk of recurrence or developing new breast cancers

The ESMO Congress 2024 will take place from September 13-17 in Barcelona, bringing together participants from all over the world

Treatment of gastrointestinal (GI) cancers is catching up with other areas of oncology and offering patients better prospects for survival and quality of life, but a significant uptick in early-onset cases is raising new questions about effective prevention, diagnosis and treatment

Cross-border tumour boards of cancer specialists from different European countries meeting virtually to review the management of individual patients with complex rare gynaecological cancers from across Europe resulted in new treatment recommendations and increased access to clinical trials, according to results from a six-year study that will be presented at the ESMO Gynaecological Cancers Congress 2024

The European Society for Medical Oncology is pleased to announce the ESMO Gastrointestinal Cancers Congress 2024, the scientific congress entirely dedicated to the presentation of advances and discussions around the prevention, diagnosis and management of malignancies of the gastrointestinal tract

The ESMO Gynaecological Cancers Congress 2024 will be held in Florence, Italy, between 20-22 June, hosting international experts who will present and discuss the latest developments in the biology, diagnosis and therapy of gynaecological tumours

Ahead of World No Tobacco Day 2024, European scientific, healthcare professional and other civil society organisations call for an EU Endgame on Tobacco